$DRRX DURECT CORP Insiders
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in DURECT CORP.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of current and past insiders in DURECT CORP. Find out how many shares they currently own, their value and whether they buy or sell their shares.
DURECT CORP Insiders
| Name | Position | Total Shares | Current Value ($) | Last 3 Months | Buy / Sell | Last Transaction | |
|---|---|---|---|---|---|---|---|
| 21 APRIL FUND LTD | 10% Owner | 21,862,770 | 22,518,653 | Sep 28 2016 | |||
| Arenberg Michael | Chief Financial Officer | 24,426 | 25,159 | Jan 19 2021 | |||
| Arnhold & S. Bleichroeder Advisers, LLC | 10% Owner | 0 | 0 | Sep 04 2019 | |||
| AZAB MOHAMMAD | Director | 0 | 0 | Jan 05 2021 | |||
| BENITO SIMON X | Director | 85,000 | 87,550 | Jun 16 2021 | |||
| BENITO SIMON X | Director | 10,000 | 10,300 | May 20 2005 | |||
| BENITO SIMON X | Director | 20,000 | 20,600 | Jun 24 2011 | |||
| BENITO SIMON X | Director | 0 | 0 | Jun 17 2014 | |||
| Blaschke Terrence F | Director | 28,000 | 28,840 | Jun 18 2020 | |||
| Blaschke Terrence F | Director | 0 | 0 | Jun 17 2014 | |||
| Bleichroeder LP | 10% Owner | 26,414,656 | 27,207,096 | Sep 02 2020 | |||
| BROWN JAMES E | President & CEO | 70,700 | 72,821 | Jan 19 2021 | |||
| BROWN JAMES E | President & CEO | 1,841,530 | 1,896,776 | Jan 10 2006 | |||
| BROWN JAMES E | President & CEO | 2,150,000 | 2,214,500 | Dec 28 2004 | |||
| BROWN JAMES E | President & CEO | 1,784,530 | 1,838,066 | Jan 21 2011 | |||
| BROWN JAMES E | President & CEO | 590,000 | 607,700 | Jan 13 2015 | |||
| CASEY MICHAEL D | Director | 0 | 0 | Jun 24 2011 | |||
| CASEY MICHAEL D | Director | 0 | 0 | Jun 26 2013 | |||
| CASEY MICHAEL D | Director | 0 | 0 | Mar 23 2004 | |||
| CASEY MICHAEL D | Director | 0 | 0 | Jun 23 2005 | |||
| CHAN TAI WAH | VP Pharma. Research & Develp. | 51,371 | 52,912 | Nov 08 2005 | |||
| Farfel Gail M | Director | 0 | 0 | Jun 18 2020 | |||
| GILLIS EDWARD M | VP Engineering | 0 | 0 | Mar 02 2004 | |||
| HALLADAY STEVEN | VP Clinical and Regulatory | 0 | 0 | Jan 10 2006 | |||
| HOFFMANN DAVE | Director | 60,000 | 61,800 | Jun 18 2020 | |||
| HOFFMANN DAVE | Director | 0 | 0 | Jun 23 2005 | |||
| HOFFMANN DAVE | Director | 0 | 0 | Jun 24 2011 | |||
| HOFFMANN DAVE | Director | 25,000 | 25,750 | Jun 17 2014 | |||
| HOGAN MATTHEW J | Chief Financial Officer | 0 | 0 | Jan 30 2018 | |||
| HOGAN MATTHEW J | Chief Financial Officer | 10,000 | 10,300 | Jan 21 2011 | |||
| HOGAN MATTHEW J | Chief Financial Officer | 0 | 0 | Jan 13 2015 | |||
| JIAN LI | VP Finance and Controller | 0 | 0 | Dec 17 2003 | |||
| JIAN LI | VP Finance and Controller | 0 | 0 | Mar 02 2004 | |||
| JIAN LI | VP Finance & Corp. Controller | 0 | 0 | Jan 10 2006 | |||
| Joice Judy R | Sr. VP Operations & Corp QA | 54,832 | 56,477 | May 17 2021 | |||
| LANGECKER PETER | Chief Medical Officer | 0 | 0 | May 26 2009 | |||
| LIU JEAN I | Sr. VP & General Counsel | 0 | 0 | Jan 10 2006 | |||
| LIU JEAN I | Sr. VP & General Counsel | 0 | 0 | Nov 08 2005 | |||
| LIU JEAN I | Chief Legal Officer | 184,627 | 190,166 | Jul 13 2011 | |||
| Mendenhall Paula V | Sr. VP of Operations | 0 | 0 | Jan 10 2006 | |||
| Mendenhall Paula V | Exec. VP of Operations/Admin. | 0 | 0 | Jan 21 2011 | |||
| Mendenhall Paula V | Exec. VP of Operations/Admin. | 0 | 0 | Feb 07 2012 | |||
| Miksztal Andrew | VP Pharmaceutical R&D | 0 | 0 | Jan 10 2006 | |||
| NELSON TIMOTHY S | Sr. VP Business & Development | 0 | 0 | Dec 21 2004 | |||
| Neukermans Armand | Director | 75,000 | 77,250 | May 26 2005 | |||
| Neukermans Armand | Director | 0 | 0 | Jun 23 2005 | |||
| Neukermans Armand | Director | 0 | 0 | Jun 24 2011 | |||
| Neukermans Armand | Director | 82,100 | 84,563 | Jun 17 2014 | |||
| Neukermans Armand | Director | 95,000 | 97,850 | Jun 18 2012 | |||
| NEUKERNONS ARNAND | Director | 38,000 | 39,140 | Jun 18 2020 | |||
| Robertson Judith J. | Director | 0 | 0 | Jun 19 2020 | |||
| SAXE JON S | Director | 125,287 | 129,046 | Jun 18 2020 | |||
| SAXE JON S | Director | 0 | 0 | Jun 23 2005 | |||
| SAXE JON S | Director | 0 | 0 | Jun 24 2011 | |||
| SAXE JON S | Director | 0 | 0 | Jun 04 2004 | |||
| SAXE JON S | Director | 27,810 | 28,644 | Jun 17 2014 | |||
| SCHRECK THOMAS A | Chief Financial Officer | 0 | 0 | Jan 16 2004 | |||
| SCHRECK THOMAS A | Chief Financial Officer | 1,865,000 | 1,920,950 | Jul 30 2004 | |||
| Shepard Jay | Director | 0 | 0 | Jun 23 2016 | |||
| Stauffer Joseph William | CMO and Exec.VP Corp. Strategy | 0 | 0 | Jan 21 2011 | |||
| Sussman Norman | Chief Medical Officer | 0 | 0 | Jan 19 2021 | |||
| TAYLOR MICHAEL J | VP, Non Clinical Research | 24,988 | 25,738 | Mar 29 2004 | |||
| THEEUWES FELIX | Chairman and CSO | 3,331,814 | 3,431,768 | Jan 30 2018 | |||
| THEEUWES FELIX | Chairman and CSO | 1,992,601 | 2,052,379 | Jan 21 2011 | |||
| THEEUWES FELIX | Chairman and CSO | 2,560,714 | 2,637,535 | Jan 13 2015 | |||
| TIPTON ARTHUR J | Sr.VP Bioerodible Product Dev. | 0 | 0 | Mar 02 2004 | |||
| YUM SU IL | Sr. VP Engineering | 0 | 0 | Jan 10 2006 | |||
| YUM SU IL | Exec. VP Pharm./R&D | 0 | 0 | Jan 21 2011 | |||
| YUM SU IL | Exec. VP Pharm./R&D | 73,454 | 75,658 | Jan 13 2015 |